Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity

(2014) Elsmarieke van de Giessen et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

(2014) Hertzel C Gerstein et al.   LANCET

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

(2014) Michael Ezrokhi et al.   Diabetology & Metabolic Syndrome

Nitric Oxide, Oxidative Stress, andp66ShcInterplay in Diabetic Endothelial Dysfunction

(2014) Alessandra Magenta et al.   Biomed Research International

The Role of Bromocriptine-QR in the Management of Type 2 Diabetes Expert Panel Recommendations

(2013) Alan Garber et al.   Endocrine Practice

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

(2013) J. Michael Gaziano et al.   Journal of the American Heart Association

The Suprachiasmatic Nucleus Controls Circadian Energy Metabolism and Hepatic Insulin Sensitivity

(2012) C. P. Coomans et al.   DIABETES

Effect of Bromocriptine-QR on Glycemic Control in Subjects with Uncontrolled Hyperglycemia on One or Two Oral Anti-Diabetes Agents

(2012) Aaron Vinik et al.   Endocrine Practice

Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats

(2012) LaxmanA Kawale et al.   INDIAN JOURNAL OF PHARMACOLOGY

Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

(2012) Yurong Zhang et al.   PLoS One

Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities

(2011) Rinrada Kietadisorn et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

(2011) R. A. DeFronzo   DIABETES CARE

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

(2011) S. Zoungas et al.   DIABETOLOGIA

Cardiovascular Disease in Diabetes: Where Does Glucose Fit In?

(2011) Jane E. B. Reusch et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

(2010) J. M. Gaziano et al.   DIABETES CARE

Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial

(2010) M. C. Riddle et al.   DIABETES CARE

Sympathetic nervous activation in obesity and the metabolic syndrome—Causes, consequences and therapeutic implications

(2010) Gavin W. Lambert et al.   PHARMACOLOGY & THERAPEUTICS

Circadian Integration of Metabolism and Energetics

(2010) J. Bass et al.   SCIENCE

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE